Pictet Asset Management Holding SA Purchases 820,284 Shares of Boston Scientific Corporation $BSX

Pictet Asset Management Holding SA increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 19.1% in the first quarter, Holdings Channel.com reports. The firm owned 5,120,057 shares of the medical equipment provider’s stock after purchasing an additional 820,284 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Boston Scientific were worth $321,301,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Cambient Family Office LLC raised its position in Boston Scientific by 30.1% in the 1st quarter. Cambient Family Office LLC now owns 3,699 shares of the medical equipment provider’s stock worth $232,000 after purchasing an additional 855 shares during the period. Pinnacle Wealth Management Advisory Group LLC boosted its position in shares of Boston Scientific by 56.9% during the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 8,452 shares of the medical equipment provider’s stock valued at $530,000 after buying an additional 3,065 shares during the period. VCI Wealth Management LLC boosted its position in shares of Boston Scientific by 55.2% during the first quarter. VCI Wealth Management LLC now owns 24,261 shares of the medical equipment provider’s stock valued at $1,522,000 after buying an additional 8,632 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its stake in shares of Boston Scientific by 72.7% during the first quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 38,000 shares of the medical equipment provider’s stock valued at $2,384,000 after buying an additional 16,000 shares during the last quarter. Finally, OLD National Bancorp IN grew its stake in shares of Boston Scientific by 193.0% during the first quarter. OLD National Bancorp IN now owns 6,320 shares of the medical equipment provider’s stock valued at $397,000 after buying an additional 4,163 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Down 0.1%

Shares of NYSE BSX opened at $44.16 on Friday. Boston Scientific Corporation has a 52-week low of $43.89 and a 52-week high of $109.50. The firm has a market capitalization of $65.64 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 0.85 and a beta of 0.56. The stock has a 50 day moving average price of $52.87 and a 200 day moving average price of $71.13. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the company posted $0.75 EPS. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a share repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Citigroup decreased their price target on Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Barclays reduced their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. UBS Group lowered their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Finally, Truist Financial cut their price target on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $83.36.

Insider Buying and Selling

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 9,800 shares of company stock valued at $554,012 over the last three months. 0.34% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.